Reviews/P2Y12 Antiplatelets/Abbreviated DAPT reduces bleeding in high bleeding risk PCI patients
Duration · P2Y12-DUR-02 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
In patients at high risk of bleeding who have a stent placed, this evidence looks at whether stopping or shortening the blood-thinning combination earlier causes fewer bleeds than continuing it longer. The central trial, MASTER DAPT, and its many patient subgroups consistently found fewer bleeding events with the shorter strategy and no rise in heart attacks, strokes or deaths [3][18][21][23], and a second stent program pointed the same way [16][19]. The panel treated this as direct, matched evidence for the claim. It also noted that the apparent weight of around twenty papers really comes from only two experiments, that the clearest reductions are in the milder category of bleeding, and that one trial comparing one versus three months did not favour the shorter option [8]. The claim is therefore well supported for bleeding overall, with the main caveats being how independent the evidence really is and how far it extends to the most serious bleeds.
The pivotal high-bleeding-risk randomised trial MASTER DAPT and its prespecified subgroups show lower BARC 2, 3 or 5 bleeding with abbreviated versus standard therapy and no excess of net adverse or ischaemic events, consistently across bifurcation [3], chronic kidney disease [18], the oral-anticoagulation strata [21], myocardial infarction [23] and sex [25] subgroups. The XIENCE Short DAPT program corroborates lower bleeding with one-month therapy, with BARC 2-5 bleeding 7.6% versus 10.0% (P=0.012) in [16] and reduced BARC 3-5 bleeding in [19]. The reduction is weighted toward milder events, for example the BARC 2 hazard ratio of 0.48 (95% CI 0.33-0.69) in [21]. Counter-signals are endpoint- or strategy-specific: major BARC 3-5 bleeding was 3.6% versus 4.7% (P=0.082) at twelve months in [16], and the aspirin-free strategy in STOPDAPT-3 [9] was not superior for major bleeding (HR 0.95; 95% CI 0.75-1.20). The contested point: The division is over how much the corpus actually independently supports the claim and on which bleeding endpoint. Most supporting records re-analyse one trial (MASTER DAPT) and one program (XIENCE Short DAPT), so roughly twenty papers reduce to two experiments, and the robust effect is in composite bleeding while major BARC 3-5 reduction is frequently non-significant [16][19]. A duration-optimisation question also intrudes: in the HBR stratum of HOST-BR [8] one-month DAPT did not reach non-inferiority to three-month DAPT.
All 25 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from P2Y12 Antiplatelets, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The corpus is dominated by re-analyses of a single RCT (MASTER DAPT appears as ~8 subgroup/secondary reports: [3][7][14][18][20][21][23][25]) plus one program (XIENCE Short DAPT: [5][16][17][19]). The apparent weight of ~21 papers reduces to roughly two independent experiments, so corpus breadth overstates evidential independence.
The bleeding reduction is driven substantially by minor (BARC type 2) events; reduction in major bleeding (BARC 3-5) alone is frequently non-significant, e.g. [16] 3.6% vs 4.7%, P=0.082. The claim 'reduces bleeding' is more robust for composite than for clinically major bleeding.
Where it remains uncertain. The weight rests on only two experiments, the effect leans on minor bleeding, and one-vs-three-month HOST-BR did not favour the shorter arm [8][16].
Aleatory
Major BARC 3-5 bleeding is infrequent, so estimates are imprecise and often non-significant despite a consistent direction, e.g. 3.6% vs 4.7% P=0.082 in [16].
The load-bearing papers from a corpus of 25, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Bleeding reduction holds across bifurcation PCI in HBR
“Abbreviated DAPT consistently reduced BARC 2, 3, or 5 bleeding in patients with (HR, 0.83 [95% CI, 0.53-1.30]) or without (HR, 0.65 [95% CI, 0.51-0.82]) bifurcation ( P interaction=0.321).”
Panel auditInternal validity: high · scope of inference: HBR PCI patients event-free at 1 month, with or without bifurcation lesions.Key limitations: bifurcation stratum CI crosses 1 · landmarked at 1 month event-free · open-label
Boundary case: within HBR, 1-month did not significantly reduce bleeding vs 3-month and trended toward ischaemic harm
“Major adverse cardiac or cerebral events occurred in 74 (9·8%) patients in the 1-month DAPT group and 44 (5·8%) in the 3-month group; bleeding occurred in 105 (13·8%) patients in the 1-month group and 122 (15·8%) in the 3-month group.”
Panel auditInternal validity: high · scope of inference: East Asian HBR PCI patients; 1 vs 3 month DAPT.Key limitations: no significance test for HBR bleeding · 1-month failed NACE non-inferiority · East Asian cohort · open-label
Independent program (XIENCE) corroborates lower composite bleeding; note major BARC 3-5 not significant
“The key secondary endpoint of BARC (Bleeding Academic Research Consortium) type 2-5 bleeding was lower with 1-month DAPT compared with 3-month DAPT (7.6% vs 10.0%; difference -2.5%; 95% CI: -4.6% to -0.3%; P = 0.012).”
Panel auditInternal validity: medium · scope of inference: HBR PCI patients with everolimus-eluting stents; 1 vs 3 month durations.Key limitations: non-randomised cross-study comparison · both arms abbreviated · major bleeding not reduced at 12 months
In anaemic HBR patients, 1-month DAPT was associated with lower major bleeding than 3-month DAPT.
Panel auditInternal validity: medium · scope of inference: HBR PCI patients with everolimus-eluting stents, anaemia subgroup; 1 vs 3 month durations.Key limitations: borderline significance · both arms abbreviated · non-randomised duration comparison
4 of 25 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Direct, replicated HBR RCT evidence carries the bleeding-reduction claim, with confidence held at the Established lower boundary because evidential breadth is inflated by re-analyses of two trial programs and the major-bleeding reduction is less consistent than the composite.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent confirmation beyond two programs. Most supporting records are re-analyses of MASTER DAPT and the XIENCE Short DAPT program, so apparent breadth overstates independence. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A new adequately powered randomised trial of abbreviated versus standard DAPT in HBR PCI patients, using different stents and investigators from MASTER DAPT and XIENCE.
Open question: Does abbreviated DAPT reduce major (BARC 3-5) bleeding, not just composite BARC 2-5 bleeding, in HBR PCI patients? Why it is still open: Composite bleeding reductions lean on minor BARC 2 events ([21] HR 0.48), while major bleeding reduction is frequently non-significant ([16] 3.6% vs 4.7%, P=0.082; [19]).
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19